BioCentury | Jul 29, 2020
Distillery Therapeutics

CAPN2 inhibition for concussion-associated neuropathy and behavioral changes

DISEASE CATEGORY: Neurology INDICATION: Neurology Inhibiting the calcium-dependent protease CAPN2 could treat neuropathy and behavioral changes caused by repeated concussions. In a mouse model of traumatic brain injury mediated by controlled cortical impact, excitatory neuron-specific...
BioCentury | Dec 20, 2019

CAPN3 gene therapy for limb-girdle muscular dystrophy type 2A

DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular dystrophy An adeno-associated viral vector deliverying CAPN3, a calcium-dependent protease expressed at low levels in the heart and primarily expressed in skeletal muscle, could treat limb-girdle muscular dystrophy type 2A...
BioCentury | Sep 27, 2019
Company News

Blade eyeing fibrosis combos with acquisition of PharmAkea-spinout

Blade is adding to its fibrosis pipeline with the acquisition of PharmAkea-spinout ATXco Inc. and its autotaxin inhibitor PAT-409. President and CEO Wendye Robbins said PAT-409 is complementary to Blade Therapeutics Inc.’s BLD-2660, a calpain...
BioCentury | Jul 25, 2019
Distillery Therapeutics

Inhibiting CAPN9 to treat fibrosis

DISEASE CATEGORY: Pulmonary; hepatic; cardiovascular INDICATION: Pulmonary fibrosis; liver fibrosis; cardiac fibrosis Inhibition of CAPN9 could treat fibrosis by blocking a TGFβ-induced pathway that contributes to fibrosis development. Two tool compound CAPN9 inhibitors decreased TGFβ-induced...
BioCentury | Jul 19, 2019
Preclinical News

July 19 Preclinical Quick Takes: Samumed's Alzheimer's candidate; plus a CRISPR RNA editing tool, new targets for fibrosis and pain

Samumed's Alzheimer's candidate reduces tau pathology, inflammation Samumed LLC (San Diego, Calif.) reported in an Aging Cell paper that SM07883 reduced tau phosphorylation, pathological tau aggregates, neuroinflammation, weight loss and mortality in a mouse model...
BioCentury | Feb 3, 2017
Financial News

Capnia financial update

On Jan. 27, inflammation, neurology and diagnostic company Capnia Inc. (NASDAQ:CAPN) entered into a 30-month stock purchase agreement with Aspire Capital Fund for up to $17 million. Capnia Inc. (NASDAQ:CAPN), Redwood City, Calif. Alicia Parker...
BioCentury | Aug 25, 2016
Distillery Therapeutics

Therapeutics: Calpain 6 (CAPN6)

Cardiovascular disease INDICATION: Atherosclerosis Patient sample and mouse studies suggest inhibiting CAPN6 could help treat atherosclerosis. In patients, CAPN6 expression on macrophages in atheromas was associated with disease severity. In a mouse model of atherosclerosis,...
BioCentury | Jul 11, 2016
Financial News

Capnia completes private placement of convertible preferred stock

Capnia Inc. (NASDAQ:CAPN), Redwood City, Calif. Business: Diagnostic Date completed: 2016-07-06 Type: Private placement of convertible preferred stock Raised: $3.2 million Shares: 3,151 Price: $1,000 Shares after offering: 15.9 million Placement agent: Maxim Group Investor:...
BioCentury | Feb 29, 2016
Clinical News

Nasal CO2: Phase II started

Capnia began a single-blind, U.S. Phase II trial to evaluate nasal CO2 in about 50 patients. Patients will receive 6 doses of nasal CO2 or placebo, with each dose given over 10 seconds, in the...
BioCentury | Jan 18, 2016
Financial News

Capnia completes private placement of convertible preferred stock and warrants

Capnia Inc. (NASDAQ:CAPN), Redwood City, Calif. Business: Diagnostic Date completed: 2016-01-11 Type: Private placement of convertible preferred stock and warrants Raised: $5.4 million Shares: 5,445 Price: $1,000 Shares outstanding prior: 12.4 million Placement agent: Maxim...
Items per page:
1 - 10 of 57